Corient Private Wealth’s Hemab Therapeutics COAG Stock Holding History
Bought
Maintained
Sold
Other funds holding COAG
SL
Corient Private Wealth's COAG Position: Q3 2026 in Review
Corient Private Wealth opened a new position in Hemab Therapeutics (COAG) in Q3 2026: 20,164 shares worth $622K. The stake represents ﹤0.01% of the portfolio and ranks #2323 among its holdings.
89 funds tracked by Wall St. Rank hold COAG as of Q3 2026.
- Corient Private Wealth held 20,164 shares of Hemab Therapeutics worth $622K as of Q3 2026.
- Hemab Therapeutics was a new Corient Private Wealth position in Q3 2026.
- Hemab Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q3 2026, its #2323 holding.
- 89 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q3 2026.
Based on Corient Private Wealth's 13F filing for Q3 2026, filed 16 Nov 2026.